At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 17 enrolled
Drug / intervention
agalsidase alfabiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Comparability Study Between Replagal® Produced From Agalsidase Alfa Manufactured by 2 Different Processes in Adult Male Patients With Fabry Disease
In Brief
A Phase 2 clinical trial evaluating agalsidase alfa for Fabry Disease. Completed, enrolled 17 participants across 5 sites.
Detailed Summary
This study is designed to evaluate safety and PK/PD in Canadian Fabry patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFabry Disease
CountriesCanada
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 2011
Enrollment StartNov 2011
Primary CompletionDec 2012
TodayJul 2026
First PostedFeb 25, 2011
Enrollment StartNov 17, 2011
Primary CompletionDec 28, 2012
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 15.4 years ago
Interventions
agalsidase alfabiological